Baiyunshan (00874.HK) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Baiyunshan Pharmaceutical Factory, recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The "Azithromycin Capsules" have passed the evaluation of generic drug quality and efficacy consistency.
According to the introduction, "Azithromycin" is mainly used to treat acute pharyngitis and acute tonsillitis caused by Streptococcus pyogenes; sinusitis, otitis media, acute bronchitis, and acute exacerbation of chronic bronchitis caused by susceptible bacteria; pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae; urethritis and cervicitis caused by Chlamydia trachomatis and Neisseria gonorrhoeae; skin and soft tissue infections caused by susceptible bacteria.
As of yesterday (18th), Baiyunshan Pharmaceutical Factory has invested approximately RMB 5.9963 million in the research and development of "Azithromycin Capsules" (js/k).
~